

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10583419
	Filing Date		2007-09-28
	First Named Inventor	Christian Hubschwerlen	
	Art Unit	1625	
	Examiner Name	R. J. Desai	
Attorney Docket Number		65507(41925)	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5808076		1998-09-15	Vetter et al.	
	2	5998436		1999-12-07	Yazaki et al.	
	3	5491139		1996-02-13	Demuth, Jr. et al.	
	4	4840956		1989-06-20	Domagala et al.	
	5	5221676		1993-06-22	Laborde et al.	
	6	6239152		2001-05-29	Gordeev et al.	
	7	5861413		1999-01-19	Habich et al.	
If you wish to add additional U.S. Patent citation information please click the Add button.						Add
U.S.PATENT APPLICATION PUBLICATIONS						Remove

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10583419
Filing Date	2007-09-28
First Named Inventor	Christian Hubschwerlen
Art Unit	1625
Examiner Name	R. J. Desai
Attorney Docket Number	65507(41925)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20040132764		2004-07-08	Locher	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	93/09103	WO	A1	1993-05-13	Upjohn Co		<input type="checkbox"/>
	2	2004/069816	WO	A1	2004-08-19	Ranbaxy Lab Ltd et al.		<input type="checkbox"/>
	3	2001/09107	WO	A1	2001-02-08	Upjohn Co et al.		<input type="checkbox"/>
	4	2000/10566	WO	A1	2000-03-02	Squibb Bristol Myers Co		<input type="checkbox"/>
	5	2167873	RU	C2	2001-05-27	Vakunaga Farmas Jutikal Ko Ltd		<input checked="" type="checkbox"/>
	6	196 01 265	DE	A1	1997-07-17	Bayer Ag		<input checked="" type="checkbox"/>
	7	2069478	JP	A	1990-03-08	Sagami Chem Res et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10583419
Filing Date		2007-09-28
First Named Inventor	Christian Hubschwerlen	
Art Unit	1625	
Examiner Name	R. J. Desai	
Attorney Docket Number	65507(41925)	

8	0 266 576	EP	A2	1988-05-11	Bristol Myers Co	<input type="checkbox"/>
9	0 390 215	EP	A2	1990-10-03	Wakunaga Seiyaku Kk	<input type="checkbox"/>
10	97/30995	WO	A1	1997-08-28	Zeneca Ltd et al.	<input type="checkbox"/>
11	99/28317	WO	A1	1999-06-10	Zeneca Ltd et al.	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Patani et al., "Bioisosterism: A Rational Approach in Drug Design", Chem. Rev., 1996, pgs. 3147-3176.	<input type="checkbox"/>
	2	Hcaplus 138:338143	<input type="checkbox"/>
	3	Hcaplus 138:304289	<input type="checkbox"/>
	4	Hcaplus 138:304288	<input type="checkbox"/>
	5	Weidner-Wells et al., Bioorg. Med. Chem., 10(7), pgs. 2345-2351 (2002).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10583419
Filing Date	2007-09-28
First Named Inventor	Christian Hubschwerlen
Art Unit	1625
Examiner Name	R. J. Desai
Attorney Docket Number	65507(41925)

6	Weidner-Wells et al., Bioorg. Med. Chem. Lett., 11(14), pgs. 1829-1832 (2001).	<input type="checkbox"/>
7	Hubschwerlen et al., "Structure-Activity Relationship in the Oxazolidinone-Quinolone Hybrid Series: Influence of the Central Spacer on the Antibacterial Activity and the Mode of Action", Bioorganic & Medicinal Chemistry Letters (2003), pgs. 4229-4233.	<input type="checkbox"/>
8	Hcaplus 141:395540	<input type="checkbox"/>
9	Selvakumar et al., "Influence of Ethylene-Oxy Spacer Group on the Activity of Linezolid: Synthesis of Potent Antibacterials Possessing a Thiocarbonyl Group", Bioorganic & Medicinal Chemistry Letters, 13 (2003), pgs. 4169-4172 (August 2003).	<input type="checkbox"/>
10	Hcaplus 141:207195, A preparation of (oxazolidinylmethyl) acetamide derivatives, useful as antimicrobial agents", August 19, 2004, Mehta et al.	<input type="checkbox"/>
11	Manfred E. Wolff et al., "Burger's Medicinal Chemistry, 5ed, Part 1" John Wiley & Sons, 1995, pgs. 975-977.	<input type="checkbox"/>
12	G.S. Banker et al., "Modern Pharmaceutics, 3ed." Marcel Dekker, New York, 1996, pgs. 451 and 596.	<input type="checkbox"/>
13	Hawley's Condensed Chemical Dictionary (1993), pg. 594	<input type="checkbox"/>
14	.W.A. Gregory et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 1. The "B" Group", J. Med. Chem. 32, pgs. 1673-1681 (1989).	<input type="checkbox"/>
15	R.T. Morrison et al., Lehrbuch der Organischen Chemie, 3, Auflage, 1986, pgs. 38-39.	<input type="checkbox"/>
16	Rompp Chemie Lexikon, 9 auflage, pgs. 1892-1893	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10583419
Filing Date	2007-09-28
First Named Inventor	Christian Hubschwerlen
Art Unit	1625
Examiner Name	R. J. Desai
Attorney Docket Number	65507(41925)

17	Abstract of Japanese Published Application No. JP200516239, published 12/05/2000	<input type="checkbox"/>
18	Dalhoff, A., "Symposium: Multiple Mode of Action Antibiotics - The Quinolone-Plus Approach", ICAAC2007, Sept. 17-20, 2007, Chicago.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.